![]() |
|
|
U.S. Department of Agriculture, Grand Forks Human Nutrition Research Center, Grand Forks, ND 58202-9034
2To whom correspondence should be addressed. E-mail: cdavis{at}gfhnrc.ars.usda.gov.
Several observations implicate a role for altered DNA methylation in cancer pathogenesis. The global level of DNA methylation is generally lower; however, DNA methyltransferase (Dnmt1) activity is usually higher in tumor cells than in normal cells. The purpose of this study was to investigate whether the Dnmt1 inhibitor, 5-aza-2'-deoxycytidine (aza-dC) would alter the effect of dietary selenium on the formation of aberrant crypts. Weanling rats (n = 60) were fed three concentrations of selenium (deficient, 0.1 and 2.0 mg/kg diet) in a Torula yeastbased diet. Half of the rats were injected weekly with aza-dC (1 mg/kg, subcutaneously) and half were injected with the vehicle control (PBS). After 3.5 wk of consuming the experimental diets, the rats were given two injections of dimethylhydrazine (DMH; 25 mg/kg, intraperitoneally). Rats fed the selenium-deficient diet and injected with PBS had significantly (P < 0.006) more aberrant crypts than rats fed 0.1 or 2.0 mg selenium/kg diet (244 ± 21 vs. 165 ± 9 and 132 ± 14, respectively). In contrast, when rats were injected with aza-dC, there was a significant (P < 0.0001) reduction in aberrant crypt formation and dietary selenium had no effect (62 ± 8 vs. 77 ± 13 vs. 54 ± 8, in rats fed 0, 0.1 and 2.0 mg selenium/kg diet, respectively). HT-29 cells cultured in the absence of selenium had significantly hypomethylated DNA but significantly more Dnmt1 protein expression than cells cultured in the presence of 1 or 2 µmol/L selenium. These results suggest that aza-dC treatment may protect selenium-deficient rats against carcinogen-induced aberrant crypt formation.
KEY WORDS: selenium DNA methylation azadeoxycytidine HT-29 DNA methyltransferase
This article has been cited by other articles:
![]() |
E. O. Uthus and S. A. Ross Dietary Selenium Affects Homocysteine Metabolism Differently in Fisher-344 Rats and CD-1 Mice J. Nutr., May 1, 2007; 137(5): 1132 - 1136. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Irons, B. A. Carlson, D. L. Hatfield, and C. D. Davis Both Selenoproteins and Low Molecular Weight Selenocompounds Reduce Colon Cancer Risk in Mice with Genetically Impaired Selenoprotein Expression J. Nutr., May 1, 2006; 136(5): 1311 - 1317. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Hu, R. V. Benya, R. E. Carroll, and A. M. Diamond Allelic Loss of the Gene for the GPX1 Selenium-Containing Protein Is a Common Event in Cancer J. Nutr., December 1, 2005; 135(12): 3021S - 3024S. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Kopelovich, J. A. Crowell, and J. R. Fay The Epigenome as a Target for Cancer Chemoprevention J Natl Cancer Inst, December 3, 2003; 95(23): 1747 - 1757. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. D. Davis and E. O. Uthus Dietary Folate and Selenium Affect Dimethylhydrazine-Induced Aberrant Crypt Formation, Global DNA Methylation and One-Carbon Metabolism in Rats J. Nutr., September 1, 2003; 133(9): 2907 - 2914. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. D. Davis and E. O. Uthus Does Dietary Selenium Affect Plasma Homocysteine Concentrations in Humans? J. Nutr., July 1, 2003; 133(7): 2392 - 2392. [Full Text] [PDF] |
||||
![]() |
B. J. Venn, A. M. Grant, C. D. Thomson, and T. J. Green Selenium Supplements Do Not Increase Plasma Total Homocysteine Concentrations in Men and Women J. Nutr., February 1, 2003; 133(2): 418 - 420. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. O. Uthus, K. Yokoi, and C. D. Davis Selenium Deficiency in Fisher-344 Rats Decreases Plasma and Tissue Homocysteine Concentrations and Alters Plasma Homocysteine and Cysteine Redox Status J. Nutr., June 1, 2002; 132(6): 1122 - 1128. [Abstract] [Full Text] [PDF] |
||||